Benzhydryl derivatives of guanidine (Formula I) having blood sugar lowering activity; pharmaceutical hypoglycemic compositions thereof and methods of administering same to hyperglycemic individuals.
N-Aryl-N'-(3-Methyl Or Ethyl-4-Oxothiazolidinylidene)Ureas Useful For The Treatment Of Epilepsy
N-aryl-N'-(3-methyl or ethyl-4-oxothiazolidinylidene)urea compounds of Formula I ##STR1## wherein: R is CH. sub. 3, C. sub. 2 H. sub. 5 ; R. sub. 1 is chosen from F, Cl, Br, CH. sub. 3, C. sub. 2 H. sub. 5, OCH. sub. 3 and CF. sub. 3 ; R. sub. 2 is H or CH. sub. 3 ; R. sub. 3 is H or F; R. sub. 4 is chosen from F, Cl, Br, CH. sub. 3, C. sub. 2 H. sub. 5, OCH. sub. 3 and CF. sub. 3 ; have anticonvulsant activity and are useful in the treatment of epilepsy.
N-(Mono- and (di-substituted phenyl)-N'-(2-imidazolidinylidene)urea compounds and acid addition salts thereof are taught, which are useful as antihypertensive agents.
Robert E. Boyd - Horsham PA Chris R. Rasmussen - Lansdale PA Jeffrey B. Press - Brewster NY
Assignee:
Ortho Pharmaceutical Corporation - Raritan NJ
International Classification:
C07D41106
US Classification:
5483151
Abstract:
The 4-[(thien-2-yl)methyl]-imidazoles of the formulae: ##STR1## wherein R is hydrogen or methyl, X is hydrogen, C. sub. 1-4 alkyl, bromine or chlorine, and Y is hydrogen, C. sub. 1-4 alkyl, bromine or chlorine; with the proviso that X and Y are not both simultaneously hydrogen. have exceptional analgesic activity.
Robert E. Boyd - Horsham PA Chris Royce Rasmussen - Lansdale PA Jeffrey B. Press - Brewster NY
Assignee:
Ortho Pharmaceutical Corporation - Raritan NJ
International Classification:
C07D41106
US Classification:
5483151
Abstract:
Described herein are 4-�(thien-3-yl)methyl!-imidazoles of the formula: ##STR1## wherein R is hydrogen or methyl, and
X is C. sub. 1-4 alkyl, bromine or chlorine; or ##STR2## wherein Y is hydrogen, C. sub. 1-4 alkyl, bromine or chlorine, and
Z is C. sub. 1-4 4alkyl, bromine or chlorine which have exceptional analgesic activity.
N-Aryl-N'-(1,4,5,6-Tetrahydropyrimidin-2-Yl)Ureas For Intestinal Disorders
N-(substituted phenyl)-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)ureas and pharmaceutically-acceptable salts thereof are disclosed to be useful in relieving the symptoms associated with irritable bowel syndrome, and as anti-diarrheal agents.
Novel 2-benzhydrylimino-1,3-diazacarbocyclic compounds of the formula ##STR1## wherein R' and R" independently are selected from the group consisting of hydrogen and methyl, X and Y independently are selected from the group consisting of hydrogen, lower alkoxy, lower alkyl and halo, and n is an integer of from 2 to 4, inclusive; and their acid addition salts are disclosed. Compounds have antisecretory properties. Certain of the compounds also have hypoglycemic properties.